EcoDrugPlus

Trace Amine Associated Receptor 1

Ensembl ID : ENSTNIG00000001335
Gene Symbol: TAAR1
2 Cross references
327 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSTNIG00000001226
Gene Symbol: TAAR1
2 Cross references
358 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSTNIG00000004515
Gene Symbol: TAAR1
2 Cross references
358 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSTNIG00000019179
Gene Symbol: TAAR1
2 Cross references
355 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSTNIG00000001410
Gene Symbol: TAAR1
2 Cross references
358 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSTNIG00000001005
Gene Symbol: TAAR1
2 Cross references
358 Possible Orthologues:

Transforming Growth Factor, Beta Receptor 1 B

Ensembl ID : ENSTNIG00000001859
Gene Symbol: TGFBR1B
2 Cross references
192 Possible Orthologues:

Transforming Growth Factor, Beta Receptor 1 B

Ensembl ID : ENSTNIG00000018951
Gene Symbol: TGFBR1B
2 Cross references
201 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1b

Ensembl ID : ENSTNIG00000008187
Gene Symbol: TRPA1B
2 Cross references
200 Possible Orthologues:

Transthyretin (Prealbumin, Amyloidosis Type I)

Ensembl ID : ENSTNIG00000010473
Gene Symbol: TTR
2 Cross references
178 Possible Orthologues:

Tryptophan Hydroxylase 1 (Tryptophan 5-Monooxygenase) A

Ensembl ID : ENSTNIG00000004167
Gene Symbol: TPH1A
2 Cross references
207 Possible Orthologues:

Tubulin Alpha 4a

Ensembl ID : ENSTNIG00000016442
Gene Symbol: TUBA4A
3 Cross references
156 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).